Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million -$235 million (previously $200 million -$225 million) and adjusted earnings per diluted share increased to $7.40 -$7.65 (previously $6.70 -$7.00) 1 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., November 6, 2025 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today r ...